Molnupiravir is an antiviral agent designed to inhibit replication of RNA viruses including SARS-CoV-2. It introduces copying errors in the viral RNA, rendering the virus non-infectious.
Recommended for:
confirmed COVID-19 cases with mild to moderate symptoms
patients at risk of complications (elderly or with chronic illnesses)
early intervention within 5 days of symptom onset
adults not requiring hospitalisation
Treatment of COVID-19 in adult patients with confirmed SARS-CoV-2 infection and risk of developing severe disease.
Take orally twice daily as prescribed, typically for 5 days. Swallow with water, with or without food.
Not recommended during pregnancy, breastfeeding, for persons under 18, or with known hypersensitivity. Possible side effects include headache, nausea, diarrhoea, and fatigue. Use only under medical supervision.
